scholarly journals Healthy and pro-inflammatory gut ecology plays a crucial role in the digestion and tolerance of a novel Gluten Friendly™ bread in celiac subjects: a randomized, double blind, placebo control in vivo study

2022 ◽  
Author(s):  
Angelo Andriulli ◽  
Antonio Bevilacqua ◽  
Orazio Palmieri ◽  
Anna Latiano ◽  
Rosanna Fontana ◽  
...  
Keyword(s):  
Crucial Role ◽  
Physicochemical Process ◽  
In Vivo Study ◽  
Placebo Control ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Gut Mucosa ◽  
Wheat Kernels

Gluten Friendly™ (GF) is a new gluten achieved through a physicochemical process applied to wheat kernels. The goal of this research was to assess the in vivo effects of Gluten Friendly™ bread on celiac gut mucosa and microbiota.

scholarly journals The role of G-CSF in recurrent implantation failure: A randomized double blind placebo control trial

2016 ◽  
Vol 14 (12) ◽  
pp. 737-742 ◽  
Author(s):  
Fatemeh Davari-tanha ◽  
Ensieh Shahrokh Tehraninejad ◽  
Mohadese Ghazi ◽  
Zahra Shahraki ◽  
◽  
...  
Keyword(s):  
Placebo Control Trial ◽  
Placebo Control ◽  
Implantation Failure ◽  
Recurrent Implantation Failure ◽  
Double Blind ◽  
Double Blind Placebo

Double-blind, placebo-controlled Alternaria alternata immunotherapy: in vivo and in vitro parameters

2007 ◽  
Vol 0 (0) ◽  
pp. 070727052443003-??? ◽  
Author(s):  
María Teresa Lizaso ◽  
Ana Isabel Tabar ◽  
Blanca Esther García ◽  
Belen Gómez ◽  
Jaime Algorta ◽  
...  
Keyword(s):  
Alternaria Alternata ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals Meta-analysis of double-blind placebo control trials evaluating the role of coenzyme Q10 on semen parameters

2018 ◽  
Vol 110 (4) ◽  
pp. e167-e168 ◽  
Author(s):  
A. Agarwal ◽  
A. Sharma ◽  
K. Master ◽  
R. Sharma ◽  
R. Henkel
Keyword(s):  
Coenzyme Q10 ◽  
Meta Analysis ◽  
Semen Parameters ◽  
Placebo Control ◽  
Double Blind ◽  
Double Blind Placebo

Metadoxine accelerates fatty liver recovery in alcoholic patients: results of a randomized double-blind, placebo-control trial

1998 ◽  
Vol 28 (1) ◽  
pp. 54-60 ◽  
Author(s):  
Joan Caballería ◽  
Albert Parés ◽  
Concepció Brú ◽  
José Mercader ◽  
Antonio Garcia Plaza ◽  
...  
Keyword(s):  
Fatty Liver ◽  
Placebo Control Trial ◽  
Placebo Control ◽  
Double Blind ◽  
Double Blind Placebo

Effect of Oral Digoxin, Topical Ouabain and Salbutamol on Transepithelial Nasal Potential Difference in Patients with Cystic Fibrosis

1995 ◽  
Vol 89 (3) ◽  
pp. 277-284 ◽  
Author(s):  
D. G. Peckham ◽  
A. Conn ◽  
C. Chotai ◽  
S. Lewis ◽  
A. J. Knox
Keyword(s):  
Cystic Fibrosis ◽  
Potential Difference ◽  
Sodium Absorption ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Control Subjects ◽  
Healthy Control ◽  
Nasal Potential Difference

1. Airway epithelium in cystic fibrosis is characterized by a defect in chloride secretion across the apical membrane and an increase in sodium absorption. The increased rate of sodium absorption can be inhibited in vitro by ouabain, a Na+-K+-ATPase inhibitor, and in cystic fibrosis patients the number and activity of nasal epithelial Na+-K+-ATPase pumps is increased. 2. We have performed a series of studies to determine whether drugs which modify airway epithelial Na+-K+-ATPase activity in vitro can modify nasal potential in cystic fibrosis patients in vivo. As transepithelial nasal potential difference measurements were used to study the effect of drug modulation of airway epithelial ion transport in vivo, the repeatability of the technique was first evaluated. In order to assess the effectiveness of the technique used for measuring nasal potential difference, a pilot study was carried out using topical amiloride, a drug which has previously been shown to inhibit airway epithelium sodium transport in vivo. We then studied the effects of ouabain and digoxin, two inhibitors of Na+-K+-ATPase, and salbutamol, a drug which activates Na+-K+-ATPase, on nasal potential difference. 3. In study 1, nasal potential difference measurements were repeated on non-consecutive days in 20 patients with cystic fibrosis and 20 healthy individuals. Healthy subjects had a mean (SEM) potential difference value of −19.5 (0.9) mV, with a 95% range for a single estimate of 75–133%. In patients with cystic fibrosis, the mean (SEM) potential difference was −40.4 (2.1) mV, with a 95% range for a single estimate of 74–136%. 4. In an initial pilot study, the effect of topical amiloride on nasal potential difference was investigated on two consecutive days in four cystic fibrosis patients and four healthy control subjects, in a double-blind, placebo-controlled, randomized cross-over study. Nasal transepithelial potential was measured before and at 5, 15, 30, 45 and 60 min after the intranasal administration of 0.4 ml of a fine spray of 1 mmol/l amiloride or 0.9% saline placebo to both nostrils. Amiloride was associated with a maximal reduction in nasal potential difference at 15 min of 49% and 41% in cystic fibrosis patients and control subjects, respectively. Compared with saline, the amiloride response was significant in both groups (P < 0.025). 5. In study 2, the effect of topical ouabain and salbutamol on nasal potential difference was investigated in ten cystic fibrosis patients and ten healthy control subjects, in a double-blind, placebo-controlled, randomized cross-over study. Nasal transepithelial potential was measured before and at 5, 15, 30, 45 and 60 min after the intranasal administration of either 0.4 ml of a fine spray of 5 mg/ml salbutamol, 0.25 mg/ml ouabain or 0.9% saline placebo to both nostrils. There was no significant change in nasal potential difference with either ouabain, salbutamol or placebo in either healthy control subjects or patients with cystic fibrosis. 6. In study 3, we performed a randomized, double-blind, placebo-controlled cross-over study of oral digoxin on nasal potential difference, spirometry and sweat electrolytes for 2 weeks in 11 patients with cystic fibrosis. During the treatment period, patients had a mean (range) serum digoxin level after the first and second week of therapy of 0.9 (0.3–1.4) μg/l and 1.1 (0.4–2.2) μg/l, respectively. There was no significant difference in the change in nasal potential difference measurements, forced expiratory volume in 1 s and sweat Na/Cl concentrations between the digoxin and placebo trial periods. 7. In conclusion, neither topical ouabain nor systemic digoxin had any effect on nasal potential difference in cystic fibrosis. Inhibitors of Na+-K+-ATPase are therefore unlikely to find a role in the treatment of cystic fibrosis. The lack of a detrimental effect of salbutamol on nasal potential difference is reassuring, as β-agonists are widely used in patients with cystic fibrosis.

Sign in / Sign up

Export Citation Format

Share Document